20 September 2023 - On 29 August 2023, the Biden administration announced the first 10 drugs whose prices will be negotiated with pharmaceutical companies through the Centers for Medicare & Medicaid Services (CMS).

CMS’ initial list features drugs that are among the most commonly used and highest in total spending in Medicare Part D, including treatments for blood clots (apixaban [Eliquis] and rivaroxaban [Xarelto]), diabetes (empagliflozin [Jardiance] and sitagliptin [Januvia]), cardiovascular disease, and cancer.

Read JAMA Viewpoint